Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice.
Q J Nucl Med
; 45(1): 18-26, 2001 Mar.
Article
en En
| MEDLINE
| ID: mdl-11456371
ABSTRACT
Bone scintigraphy continues to be one of the most commonly performed procedures in nuclear medicine. The radionuclide bone scan remains an excellent modality to detect metastatic disease in patients suffering from primary malignancies. This article reviews a number of aspects of bone scintigraphy such as bone physiology, radiopharmaceuticals and uptake mechanisms. As 99mTc labelled bis(di)phosphonates are the most frequently used this article is centred around these imaging agents. In addition to diagnostic bone scintigraphy the use of various bone seeking agents has been extended to the palliative treatment of bone metastases. In this context the radiobiological characteristics of various radionuclides as 89Sr, 32p, 153Sm, 186Re and 117Sn is elucidated. In addition, the clinical efficacy for pain killing of these radionuclides is elucidated on the basis of the radiation properties of these agents. It is concluded that 89Sr and 186Re are presently the radionuclides of choice. The latter agent has a slight advantage as its imaging photons enable individual dosimetry, resulting in an optimosed application scheme.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Óseas
/
Radiofármacos
Límite:
Humans
Idioma:
En
Revista:
Q J Nucl Med
Asunto de la revista:
MEDICINA NUCLEAR
Año:
2001
Tipo del documento:
Article
País de afiliación:
Países Bajos